HDAC9 and cancer: The top-performing drug models include targeted therapies against well-known cancer targets such as ERBBs, HDAC, BCL2, JAKs, PARP, ERK, CDKs, etc., and Lapatinib, Vincristine, and CAY10603 presented the best performing models with an average AUROC more than 0.9.